Items Tagged ‘human epidermal growth factor receptor-negative’

February 27th, 2015

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer

By

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer progression when used as first-line treatment for advanced breast cancer in postmenopausal women with estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)-negative disease. […]

View full entry

Tags: Breast Cancer, ER-positive, estrogen receptor-positive, Femara, HER-2 negative, human epidermal growth factor receptor-negative, Ibrance, kinase inhibitor, letrozole, Metastatic Breast Cancer, News, palbociclib